Salvage therapy with basiliximab and etanercept for severe steroid‐refractory acute graft‐versus‐host disease-Reference-Cited by-同舟云学术

Salvage therapy with basiliximab and etanercept for severe steroid‐refractory acute graft‐versus‐host disease

Published:2022-04-22 Issue:7 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Freyer Craig W.¹^ORCID,Gier Shannon²,Carulli Alison¹,Gill Saar I.²,Hexner Elizabeth O.²,Loren Alison W.²,Martin Mary Ellen²,Porter David L.²

Affiliation:

1. Department of Pharmacy Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA

2. Blood and Marrow Transplant and Cellular Therapy Program, Abramson Cancer Center Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26568

Reference6 articles.

1. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

2. Ruxolitinib combined with etanercept induce a rapid response to corticosteroid‐refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi‐center prospective study

3. Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease : Updated experience from a large‐scale study

4. Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis

5. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia;Frontiers in Immunology;2022-11-15